Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology



Status:Enrolling by invitation
Conditions:Parkinsons Disease, Neurology, Neurology, Orthopedic
Therapuetic Areas:Neurology, Orthopedics / Podiatry
Healthy:No
Age Range:18 - 70
Updated:2/9/2019
Start Date:January 1, 2018
End Date:December 31, 2020

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This study occurs during five visits that are already scheduled as part of "Biomarkers to
Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688).
If participants have dystonia associated with Parkinson's disease, the investigators will
consent and administer one additional rating scale (Burke-Fahn-Marsden Dystonia Rating Scale)
to assess the severity of dystonia.

To measure the effects of DBS on dystonia, the investigators will measure the change in the
Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery versus
preoperative baseline. This will allow them to contrast the effects of omnidirectional versus
directional STN DBS on dystonia symptoms in patients with PD.

Inclusion Criteria:

- Enrollment in "Biomarkers to Guide Directional DBS for Parkinson's Disease"
(ClinicalTrials.gov Identifier: NCT03353688)

- Diagnosis of Parkinson's disease with and without dystonia

Exclusion Criteria:

- Not enrolled in "Biomarkers to Guide Directional DBS for Parkinson's Disease"
(ClinicalTrials.gov Identifier: NCT03353688)
We found this trial at
1
site
University of Alabama at Birmingham
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials